Semaglutide is a long-acting analog of glucagon-like peptide-1. It binds the GLP-1 receptor, a class B GPCR expressed on pancreatic beta cells, and potentiates glucose-dependent insulin secretion while suppressing glucagon release. Structural modification — an Aib substitution at position 8 resisting DPP-4 cleavage, plus a C18 fatty diacid that drives reversible albumin binding — extends half-life to roughly one week. Central GLP-1 receptors in the hypothalamus and hindbrain mediate reduced appetite and energy intake; gastric emptying is slowed.
Among the most extensively studied peptides in medicine. The SUSTAIN programme established glycaemic efficacy in type 2 diabetes, STEP established weight reduction in obesity, and SELECT reported cardiovascular outcome benefit in patients with established cardiovascular disease and overweight or obesity. Evidence base spans tens of thousands of randomised participants.
FDA-approved. Marketed for type 2 diabetes, chronic weight management, and cardiovascular risk reduction depending on the specific product. Prescription-only. FDA issued a large volume of warning letters during 2025 to entities marketing compounded or research-labelled semaglutide.
Boxed warning for thyroid C-cell tumours observed in rodents; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2. Common gastrointestinal effects. Signals for pancreatitis, gallbladder disease, and (with rapid loss) lean mass reduction. Requires physician supervision.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.